9,10-Dihydroacridine
Based on 1 Customer Validation
9,10-Dihydroacridine is a chain-terminating antioxidant that can inhibit lipid peroxidation by capturing peroxide free radicals (LOO•).
For research use only. We do not sell to patients.
- Purity : 99.75%
- CAS No.: 92-81-9
- Formula: C13H11N
- Molecular Weight:181.23
-
Storage:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-B1422
9-AminoacridineAntimicrobial -
HY-B2174
Ethacridine lactateAntiseptic Agent -
HY-W004606
9,9-Dimethyl-9,10-dihydroacridineElectron-Donating Group -
HY-W015051
Carbamazepine impurity 7Drug Impurity -
HY-W011950
Acridin-9-amine hydrochloride hydrateMutagen -
HY-W022759
9-Acridinecarboxylic acid -
HY-B1422R
9-Aminoacridine (Standard)Antimicrobial -
HY-W015051R
9-Methylacridine (Standard) -
HY-W104195A
3,6-Diaminoacridine hydrochloride, 98%Antibacterial Agent
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RBL-1 | IC50 |
1.6 μM
Compound: 32
|
In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells
In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells
|
[PMID: 2113951] |
| RBL-1 | IC50 |
1.9 μM
Compound: 32
|
In vitro inhibition of Prostaglandin G/H synthase pathway in rat basophilic leukemia (RBL-1) cells
In vitro inhibition of Prostaglandin G/H synthase pathway in rat basophilic leukemia (RBL-1) cells
|
[PMID: 2113951] |
| U-937 | IC50 |
0.68 μM
Compound: 4
|
Cytotoxicity in UV-irradiated human U937 cells exposed to photosensitizer for 2 hrs before irradiation for 20 mins by WST-1 assay
Cytotoxicity in UV-irradiated human U937 cells exposed to photosensitizer for 2 hrs before irradiation for 20 mins by WST-1 assay
|
[PMID: 24900465] |
Chemical Information
-
CAS No. 92-81-9
-
Appearance Solid
-
Molecular Weight 181.23
-
Formula C13H11N
-
Color Light yellow to yellow
-
SMILES
C12=C(NC3=C(C2)C=CC=C3)C=CC=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Solvent & Solubility
In Vitro:
DMSO : 10 mg/mL (55.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 5.5179 mL | 27.5893 mL | 55.1785 mL | 137.9463 mL |
| 5 mM | 1.1036 mL | 5.5179 mL | 11.0357 mL | 27.5893 mL | |
| 10 mM | 0.5518 mL | 2.7589 mL | 5.5179 mL | 13.7946 mL | |
| 15 mM | 0.3679 mL | 1.8393 mL | 3.6786 mL | 9.1964 mL | |
| 20 mM | 0.2759 mL | 1.3795 mL | 2.7589 mL | 6.8973 mL | |
| 25 mM | 0.2207 mL | 1.1036 mL | 2.2071 mL | 5.5179 mL | |
| 30 mM | 0.1839 mL | 0.9196 mL | 1.8393 mL | 4.5982 mL | |
| 40 mM | 0.1379 mL | 0.6897 mL | 1.3795 mL | 3.4487 mL | |
| 50 mM | 0.1104 mL | 0.5518 mL | 1.1036 mL | 2.7589 mL |
9,10-Dihydroacridine Related Classifications
HY-W129155 Related Classifications
Powered by Bioz